Celldex highlights survival data from PhII cancer drug study; Allergan to buy skin products maker for $350M;

Conversations on Twitter :

 @FierceBiotech: Novartis grabs EU committee support for first meningitis B vaccine. Article | Follow @FierceBiotech

 @JohnCFierce: Somehow doubt that Biocon really wanted an option deal for IN-105, its oral insulin program. More | Follow @JohnCFierce

 @RyanMFierce: Dynavax stock in pre-market meltdown mode after adcomm on hep B vax didn't back safety. More | Follow @RyanMFierce

> Celldex Therapeutics ($CLDX) reported upbeat three-year survival data from a Phase II study of its drug rindopepimut against glioblastoma. Release

> The Michael J. Fox Foundation highlighted SynAgile, Durin Technologies and Sapiens as fourth-quarter industry partners working on improving treatment of patients with Parkinson's disease. Release

> Allergan ($AGN) aims to scoop up SkinMedica in a $350 million deal to add new skin products. News

Pharma News

@FiercePharma: Whistleblower lawsuit on Pfizer's Lipitor dismissed. Story | Follow @FiercePharma

> Novartis vaccines get booster shot with EMA nod for Bexsero. Story

> GlaxoSmithKline to pay out $90M more for Avandia claims. Article

Medical Device News

 @FierceMedDev: Cyberonics, a maker of neuromodulation devices, had a great Fy2013 Q2. Story | Follow @FierceMedDev

 @MarkHFierce: Thermo Fisher unveiled a new manufacturing facility in China. Item | Follow @MarkHFierce

 @DamianFierce: As advocates fight to repeal the device tax, we take a detailed look at how the 2.3% charge would work. Special Report | Follow @DamianFierce

> Cook nabs FDA approval for drug-eluting stent to treat PAD. News

> Dx startup Quanterix draws major bioMérieux investment. Article

> 'Fiscal cliff' overshadows push for device tax repeal. Story

And Finally… Amid an effort to raise awareness of diabetes, the Centers for Disease Control and Prevention emphasized fast growth in patients afflicted with disease in southern U.S. states. Article

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.